Bristol-Myers Squibb Company (BMY) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

BMY Stock Forecast


Bristol-Myers Squibb Company stock forecast is as follows: an average price target of $64.57 (represents a 16.45% upside from BMY’s last price of $55.45) and a rating consensus of 'Hold', based on 18 wall street analysts offering a 1-year stock forecast.

BMY Price Target


The average price target for Bristol-Myers Squibb Company (BMY) is $64.57 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $85.00 to $41.00. This represents a potential 16.45% upside from BMY's last price of $55.45.

BMY Analyst Ratings


Hold

According to 18 Wall Street analysts, Bristol-Myers Squibb Company's rating consensus is 'Hold'. The analyst rating breakdown for BMY stock is 0 'Strong Buy' (0.00%), 6 'Buy' (33.33%), 11 'Hold' (61.11%), 1 'Sell' (5.56%), and 0 'Strong Sell' (0.00%).

Bristol-Myers Squibb Company Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 23, 2024Evan David SeigermanBMO Capital$48.00$49.56-3.15%-13.44%
Jul 29, 2024Chris ShibutaniGoldman Sachs$57.00$50.5512.77%2.80%
Jul 29, 2024Carter GouldBarclays$41.00$50.45-18.73%-26.06%
Jul 12, 2024Trung HuynhUBS$43.00$40.685.70%-22.45%
May 16, 2024Steve ScalaCowen & Co.$67.00$44.1151.89%20.83%
Jan 30, 2024James ShinDeutsche Bank$55.00$49.8710.29%-0.81%
Nov 27, 2023Evan SeigermanBMO Capital$60.00$49.7620.58%8.21%
Oct 12, 2023David RisingerLeerink Partners$66.00$56.2417.34%19.03%
Sep 06, 2023Louise ChenCantor Fitzgerald$75.00$59.6725.69%35.26%
May 18, 2022Mohit BansalWells Fargo$70.00$78.22-10.51%26.24%
Row per page
Go to

The latest Bristol-Myers Squibb Company stock forecast, released on Sep 23, 2024 by Evan David Seigerman from BMO Capital, set a price target of $48.00, which represents a -3.15% decrease from the stock price at the time of the forecast ($49.56), and a -13.44% decrease from BMY last price ($55.45).

Bristol-Myers Squibb Company Price Target by Period


1M3M12M
# Anlaysts-17
Avg Price Target-$48.00$53.00
Last Closing Price$55.45$55.45$55.45
Upside/Downside-100.00%-13.44%-4.42%

In the current month, the average price target of Bristol-Myers Squibb Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bristol-Myers Squibb Company's last price of $55.45. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 17, 2024Bernstein-Market PerformInitialise
Oct 09, 2024UBSNeutralNeutralHold
Oct 07, 2024JefferiesMarket PerformMarket PerformHold
Oct 07, 2024Deutsche BankUnderperformUnderperformHold
Oct 07, 2024BarclaysUnderweightUnderweightHold
Sep 23, 2024BMO CapitalMarket PerformMarket PerformHold
Sep 16, 2024Goldman SachsBuyBuyHold
Aug 28, 2024JefferiesHoldHoldHold
Aug 22, 2024Deutsche BankEqual-WeightEqual-WeightHold
Aug 22, 2024BarclaysUnderweightUnderweightHold
Row per page
Go to

Bristol-Myers Squibb Company's last stock rating was published by Bernstein on Oct 17, 2024. The company Initialise its BMY rating from "null" to "Market Perform".

Bristol-Myers Squibb Company Financial Forecast


Bristol-Myers Squibb Company Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$10.97B$11.23B$11.34B$11.41B$11.22B$11.89B$11.65B$11.98B$11.62B$11.70B$11.07B$11.07B$10.54B$10.13B$10.78B$7.95B$6.01B
Avg Forecast$11.34B$11.29B$11.43B$11.06B$11.78B$11.62B$11.91B$11.71B$11.53B$11.26B$11.54B$11.48B$11.19B$10.96B$11.77B$11.50B$11.19B$11.14B$11.42B$11.36B$12.04B$11.61B$11.27B$11.13B$10.73B$10.32B$9.99B$10.03B$7.12B$5.90B
High Forecast$11.48B$11.42B$11.56B$11.19B$11.91B$11.76B$12.05B$11.73B$11.69B$11.27B$11.54B$11.50B$11.53B$11.16B$11.90B$11.63B$11.31B$11.14B$11.42B$11.36B$12.04B$11.61B$11.27B$11.13B$10.73B$10.32B$9.99B$10.03B$7.12B$5.90B
Low Forecast$11.19B$11.13B$11.27B$10.90B$11.61B$11.46B$11.75B$11.69B$11.40B$11.26B$11.54B$11.47B$10.78B$10.82B$11.60B$11.34B$11.03B$11.14B$11.42B$11.36B$12.04B$11.61B$11.27B$11.13B$10.73B$10.32B$9.99B$10.03B$7.12B$5.90B
# Analysts11111112126749168912778138891359644
Surprise %-------------1.00%0.95%0.99%1.02%1.01%1.04%1.03%1.00%1.00%1.04%0.99%1.03%1.02%1.01%1.08%1.12%1.02%

Bristol-Myers Squibb Company's average Quarter revenue forecast for Dec 23 based on 9 analysts is $11.19B, with a low forecast of $10.78B, and a high forecast of $11.53B. BMY's average Quarter revenue forecast represents a 2.06% increase compared to the company's last Quarter revenue of $10.97B (Sep 23).

Bristol-Myers Squibb Company EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111112126749168912778138891359644
EBITDA-------------$4.21B$4.16B$5.10B$4.71B$5.30B$5.39B$5.08B$4.76B$5.21B$4.59B$5.54B$-7.41B$5.25B$4.54B$2.53B$1.39B$1.72B
Avg Forecast$4.30B$4.28B$4.33B$4.19B$4.46B$4.40B$4.51B$4.44B$4.37B$4.27B$4.37B$5.03B$4.24B$4.15B$4.46B$4.57B$4.82B$4.22B$4.32B$4.15B$4.56B$4.40B$4.27B$5.79B$4.06B$3.91B$3.78B$2.14B$2.70B$2.23B
High Forecast$4.35B$4.33B$4.38B$4.24B$4.51B$4.45B$4.56B$4.44B$4.43B$4.27B$4.37B$6.03B$4.37B$4.23B$4.51B$5.48B$5.79B$4.22B$4.32B$4.99B$4.56B$4.40B$4.27B$6.94B$4.06B$3.91B$3.78B$2.56B$2.70B$2.23B
Low Forecast$4.24B$4.22B$4.27B$4.13B$4.40B$4.34B$4.45B$4.43B$4.32B$4.26B$4.37B$4.02B$4.08B$4.10B$4.39B$3.66B$3.86B$4.22B$4.32B$3.32B$4.56B$4.40B$4.27B$4.63B$4.06B$3.91B$3.78B$1.71B$2.70B$2.23B
Surprise %-------------1.02%0.93%1.12%0.98%1.26%1.25%1.22%1.04%1.18%1.08%0.96%-1.82%1.34%1.20%1.18%0.52%0.77%

9 analysts predict BMY's average Quarter EBITDA for Dec 23 to be $4.24B, with a high of $4.37B and a low of $4.08B. This is 0.57% upper than Bristol-Myers Squibb Company's previous annual EBITDA (Sep 23) of $4.21B.

Bristol-Myers Squibb Company Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111112126749168912778138891359644
Net Income-------------$1.93B$2.07B$2.26B$2.02B$1.61B$1.42B$1.28B$2.37B$1.55B$1.05B$2.02B$-10.03B$1.87B$-85.00M$-775.00M$-1.06B$1.35B
Avg Forecast$3.49B$4.05B$3.73B$3.24B$3.47B$3.74B$3.86B$3.74B$3.02B$3.03B$3.29B$1.51B$3.15B$3.58B$3.98B$1.37B$2.59B$3.71B$3.59B$1.24B$3.64B$3.89B$3.83B$2.11B$2.87B$3.02B$3.01B$-655.37M$1.79B$2.18B
High Forecast$3.54B$4.11B$3.79B$3.29B$3.53B$3.79B$3.92B$4.02B$3.18B$3.13B$3.29B$1.81B$3.55B$3.78B$4.04B$1.64B$3.10B$3.71B$3.59B$1.49B$3.74B$3.89B$3.83B$2.53B$2.87B$3.02B$3.01B$-524.30M$1.79B$2.18B
Low Forecast$3.43B$3.98B$3.67B$3.18B$3.41B$3.67B$3.79B$3.49B$2.84B$2.94B$3.29B$1.20B$2.86B$3.40B$3.91B$1.10B$2.07B$3.71B$3.59B$995.64M$3.55B$3.89B$3.83B$1.69B$2.87B$3.02B$3.01B$-786.44M$1.79B$2.18B
Surprise %-------------0.54%0.52%1.65%0.78%0.43%0.40%1.03%0.65%0.40%0.28%0.96%-3.49%0.62%-0.03%1.18%-0.59%0.62%

Bristol-Myers Squibb Company's average Quarter net income forecast for Dec 23 is $3.15B, with a range of $2.86B to $3.55B. BMY's average Quarter net income forecast represents a 63.51% increase compared to the company's last Quarter net income of $1.93B (Sep 23).

Bristol-Myers Squibb Company SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111112126749168912778138891359644
SG&A-------------$2.00B$1.93B$1.76B$2.27B$1.93B$1.79B$1.83B$2.35B$1.79B$1.88B$1.67B$2.72B$1.71B$1.63B$1.61B$1.73B$1.05B
Avg Forecast$1.98B$1.97B$2.00B$1.93B$2.06B$2.03B$2.08B$2.05B$2.02B$1.97B$2.02B$2.16B$1.96B$1.92B$2.06B$1.96B$2.55B$1.95B$2.00B$1.78B$2.11B$2.03B$1.97B$1.74B$1.88B$1.80B$1.75B$1.36B$1.24B$1.03B
High Forecast$2.01B$2.00B$2.02B$1.96B$2.08B$2.06B$2.11B$2.05B$2.04B$1.97B$2.02B$2.59B$2.02B$1.95B$2.08B$2.35B$3.06B$1.95B$2.00B$2.14B$2.11B$2.03B$1.97B$2.09B$1.88B$1.80B$1.75B$1.63B$1.24B$1.03B
Low Forecast$1.96B$1.95B$1.97B$1.91B$2.03B$2.00B$2.05B$2.04B$1.99B$1.97B$2.02B$1.73B$1.88B$1.89B$2.03B$1.57B$2.04B$1.95B$2.00B$1.43B$2.11B$2.03B$1.97B$1.39B$1.88B$1.80B$1.75B$1.09B$1.24B$1.03B
Surprise %-------------1.05%0.94%0.90%0.89%0.99%0.89%1.03%1.12%0.88%0.96%0.96%1.45%0.95%0.93%1.18%1.39%1.02%

Bristol-Myers Squibb Company's average Quarter SG&A projection for Dec 23 is $1.96B, based on 9 Wall Street analysts, with a range of $1.88B to $2.02B. The forecast indicates a -2.30% fall compared to BMY last annual SG&A of $2.00B (Sep 23).

Bristol-Myers Squibb Company EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111112126749168912778138891359644
EPS-------------$0.94$0.99$1.08$0.96$0.75$0.67$0.60$1.10$0.70$0.47$0.90$-4.45$0.83$-0.04$-0.34$-0.55$0.83
Avg Forecast$1.72$2.00$1.84$1.60$1.71$1.84$1.90$1.84$1.49$1.49$1.62$-4.41$1.55$1.76$1.96$1.97$1.73$1.83$1.77$1.91$1.80$1.92$1.89$1.81$1.42$1.49$1.48$1.49$0.88$1.07
High Forecast$1.75$2.03$1.87$1.62$1.74$1.87$1.93$1.98$1.57$1.54$1.62$-4.33$1.75$1.86$1.99$2.00$1.75$1.83$1.77$1.91$1.84$1.92$1.89$1.81$1.42$1.49$1.48$1.49$0.88$1.07
Low Forecast$1.69$1.96$1.81$1.57$1.68$1.81$1.87$1.72$1.40$1.45$1.62$-4.48$1.41$1.67$1.93$1.94$1.70$1.83$1.77$1.91$1.75$1.92$1.89$1.81$1.42$1.49$1.48$1.49$0.88$1.07
Surprise %-------------0.53%0.50%0.55%0.56%0.41%0.38%0.31%0.61%0.36%0.25%0.50%-3.14%0.56%-0.03%-0.23%-0.62%0.77%

According to 9 Wall Street analysts, Bristol-Myers Squibb Company's projected average Quarter EPS for Dec 23 is $1.55, with a low estimate of $1.41 and a high estimate of $1.75. This represents a 65.29% increase compared to BMY previous annual EPS of $0.94 (Sep 23).

Bristol-Myers Squibb Company Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PFEPfizer$27.76$44.7661.24%Hold
BIIBBiogen$173.52$276.3859.28%Buy
MRKMerck$101.87$129.4727.09%Buy
BMYBristol-Myers Squibb Company$55.45$64.5716.45%Hold
JNJJohnson & Johnson$158.24$179.1313.20%Buy
LLYEli Lilly and Company$806.14$782.65-2.91%Buy
AMGNAmgen$316.91$293.15-7.50%Buy
GILDGilead Sciences$89.84$81.32-9.48%Buy
ABBVAbbVie$200.47$174.04-13.18%Buy

BMY Forecast FAQ


No, according to 18 Wall Street analysts, Bristol-Myers Squibb Company (BMY) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 33.33% of BMY's total ratings.

Bristol-Myers Squibb Company (BMY) average price target is $64.57 with a range of $41 to $85, implying a 16.45% from its last price of $55.45. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for BMY stock, the company can go up by 16.45% (from the last price of $55.45 to the average price target of $64.57), up by 53.29% based on the highest stock price target, and down by -26.06% based on the lowest stock price target.

BMY's highest twelve months analyst stock price target of $85 supports the claim that Bristol-Myers Squibb Company can reach $80 in the near future.

Bristol-Myers Squibb Company's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $47.03B (high $47.45B, low $46.52B), average EBITDA is $17.81B (high $17.97B, low $17.62B), average net income is $14.81B (high $15.26B, low $14.37B), average SG&A $8.22B (high $8.3B, low $8.13B), and average EPS is $7.3 (high $7.52, low $7.08). BMY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $45.12B (high $45.64B, low $44.49B), average EBITDA is $17.09B (high $17.29B, low $16.85B), average net income is $14.52B (high $14.73B, low $14.25B), average SG&A $7.89B (high $7.98B, low $7.78B), and average EPS is $7.15 (high $7.26, low $7.03).

Based on Bristol-Myers Squibb Company's last annual report (Dec 2023), the company's revenue was $45.01B, which missed the average analysts forecast of $45.41B by -0.89%. Apple's EBITDA was $17.24B, missing the average prediction of $17.41B by -0.99%. The company's net income was $8.02B, missing the average estimation of $12.08B by -33.57%. Apple's SG&A was $7.77B, missing the average forecast of $7.89B by -1.51%. Lastly, the company's EPS was $3.88, missing the average prediction of $7.25 by -46.49%. In terms of the last quarterly report (Sep 2023), Bristol-Myers Squibb Company's revenue was $10.97B, beating the average analysts' forecast of $10.96B by 0.10%. The company's EBITDA was $4.22B, beating the average prediction of $4.15B by 1.59%. Bristol-Myers Squibb Company's net income was $1.93B, missing the average estimation of $3.58B by -46.14%. The company's SG&A was $2B, beating the average forecast of $1.92B by 4.56%. Lastly, the company's EPS was $0.94, missing the average prediction of $1.76 by -46.72%